NASDAQ:BVS Bioventus (BVS) Stock Price, News & Analysis $9.88 -0.07 (-0.70%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$9.90 +0.01 (+0.15%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Bioventus Stock (NASDAQ:BVS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bioventus alerts:Sign Up Key Stats Today's Range$9.81▼$10.1750-Day Range$9.88▼$15.0452-Week Range$6.47▼$15.89Volume612,434 shsAverage Volume701,226 shsMarket Capitalization$832.49 millionP/E Ratio12.35Dividend YieldN/APrice Target$16.60Consensus RatingModerate Buy Company Overview Bioventus Inc. is a medical technology company focused on helping patients recover from musculoskeletal conditions and injuries. Its products and services support bone healing, pain management and surgical care. The company’s offerings include noninvasive devices that use ultrasound to support bone healing, injectable treatments for osteoarthritis pain, and surgical products such as bone graft materials and ultrasonic instruments used in procedures. Bioventus began operations in 2012, originating from businesses previously owned by Smith & Nephew. It serves healthcare providers and patients in the United States and international markets.AI Generated. May Contain Errors. Read More Bioventus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreBVS MarketRank™: 3.81032547699 of 5 starsBioventus scored higher than 76% of companies evaluated by MarketBeat, and ranked 120th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingBioventus has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialBioventus has a consensus price target of $16.60, representing about 68.0% upside from its current price of $9.88.Amount of Analyst CoverageBioventus has only been the subject of 2 research reports in the past 90 days.Read more about Bioventus' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth12.82% Earnings GrowthEarnings for Bioventus are expected to grow by 12.82% in the coming year, from $0.78 to $0.88 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bioventus is 12.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.19.Price to Earnings Ratio vs. SectorThe P/E ratio of Bioventus is 12.35, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.56.Price to Earnings Growth RatioBioventus has a PEG Ratio of 1.27. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBioventus has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.39% of the float of Bioventus has been sold short.Short Interest Ratio / Days to CoverBioventus has a short interest ratio ("days to cover") of 6.62.Change versus previous monthShort interest in Bioventus has recently decreased by 4.88%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioventus does not currently pay a dividend.Dividend GrowthBioventus does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.92 News SentimentBioventus has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bioventus this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for BVS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows4 people have added Bioventus to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bioventus insiders have not sold or bought any company stock.Percentage Held by Insiders33.50% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bioventus' insider trading history. Receive BVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BVS Stock News HeadlinesBioventus Inc. (NASDAQ:BVS) Stock Has Consensus Price Target of $16.60 According to Analysts30 minutes ago | americanbankingnews.comBioventus Earnings Call Highlights Growth Amid HeadwindsNovember 15, 2026 | theglobeandmail.comSeven bucks, yours for life: my Black Friday indicator dealBase Camp Trading's Thomas Wood is giving away his proprietary Snapback Indicator for just $7 this Black Friday. Others paid $500 for it. It's a one-time price with no recurring billing, and the indicator is yours for life. It shows when it's time to sell or go short, and when it makes sense to buy. Check it for a potential Snapback before your next trade. | Base Camp Trading (Ad)Bioventus Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 5, 2026 | seekingalpha.comBioventus (BVS) Stock Price Slides After Q3 Results Cut Revenue OutlookNovember 4, 2026 | finance.yahoo.comBioventus Reports Higher Q3 Profit, Cuts 2026 Sales Outlook; Stock DownNovember 3, 2026 | rttnews.comBioventus (BVS) Q3 2026 Earnings Call TranscriptNovember 3, 2026 | finance.yahoo.comBioventus expects 2026 revenue of $590M-$595M while reaffirming adjusted EPS of $0.75-$0.79November 3, 2026 | seekingalpha.comSee More Headlines BVS Stock Analysis - Frequently Asked Questions How have BVS shares performed this year? Bioventus' stock was trading at $7.44 at the start of the year. Since then, BVS stock has increased by 32.8% and is now trading at $9.88. How were Bioventus' earnings last quarter? Bioventus Inc. (NASDAQ:BVS) announced its earnings results on Monday, November, 2nd. The company reported $0.17 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.17. The firm earned $142.44 million during the quarter. Bioventus had a net margin of 9.78% and a trailing twelve-month return on equity of 26.31%. Read the conference call transcript. When did Bioventus IPO? Bioventus (BVS) raised $136 million in an initial public offering on Thursday, February 11th 2021. The company issued 8,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO. Who are Bioventus' major shareholders? Bioventus' top institutional investors include Nantahala Capital Management LLC (7.62%), American Century Companies Inc. (2.57%), Royce & Associates LP (1.91%) and State Street Corp (1.39%). Insiders that own company stock include John A Bartholdson, Mark Leonard Singleton, Anthony D'adamio, Guy P Nohra, Robert E Claypoole, Katrina J Church and Michelle Mcmurry-Heath. View institutional ownership trends. How do I buy shares of Bioventus? Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bioventus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioventus investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Tesla (TSLA), Alibaba Group (BABA), Intel (INTC), Micron Technology (MU) and Walt Disney (DIS). Company Calendar Last Earnings11/02/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, BVS's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:BVS Previous SymbolNASDAQ:BVS CIK1665988 Webbioventus.com Phone(919) 474-6700FaxN/AEmployees960Year Founded2012Price Target and Rating Average Price Target for Bioventus$16.60 High Price Target$18.00 Low Price Target$14.00 Potential Upside/Downside+68.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.80 Trailing P/E Ratio12.35 Forward P/E Ratio11.23 P/E Growth1.27Net Income$22.73 million Net Margins9.78% Pretax Margin6.85% Return on Equity26.31% Return on Assets10.13% Debt Debt-to-Equity Ratio0.72 Current Ratio1.68 Quick Ratio1.16 Sales & Book Value Annual Sales$568.09 million Price / Sales1.47 Cash Flow$1.27 per share Price / Cash Flow7.75 Book Value$3.46 per share Price / Book2.86Miscellaneous Outstanding Shares84,260,000Free Float56,034,000Market Cap$832.49 million OptionableOptionable Beta0.66 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:BVS) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored“IMPERIUM”: The #1 investment of 2027Could a strange new bio-chip be the most transformative innovation in history? Elon Musk calls it "amazing." A...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.